Ann: IHL Receives Ethics Approval for Phase 2 OSA Trial, page-11

Real interesting that IHL is choosing to add epilepsy as a secondary endpoint thanks to Prof O'Brien's expertise in the subject.

That was not at all present in any of the previous US based dronabinol trials. Would be real nice if we were to achieve statistically significant change in reducing seizure frequency at all.

I am waiting for the start and expected end date of the trial to be released...
After seeing what happened to BOT yesterday, pretty clear that punters are getting on board in expectation of a positive Phase 2A result for them.
Should get that kind of interest when IHL gives guidance on commencement of the trial.

Hope the impact of this ann is factored in as soon as oppies cease trading by today's end. Onwards and upwards!